Total Payments
$12,801
2024 Payments
$2,817
Companies
28
Transactions
677
Medicare Patients
1,119
Medicare Billing
$215,470
Payment Breakdown by Category
Food & Beverage$12,706 (99.3%)
Education$95.75 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,706 | 675 | 99.3% |
| Education | $95.75 | 2 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $1,872 | 99 | $0 (2024) |
| ABBVIE INC. | $1,564 | 115 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,505 | 86 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $1,013 | 49 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,013 | 44 | $0 (2024) |
| Lundbeck LLC | $835.26 | 44 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $713.44 | 26 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $679.61 | 51 | $0 (2022) |
| ITI, Inc. | $598.20 | 26 | $0 (2023) |
| Axsome Therapeutics, Inc. | $446.58 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,817 | 148 | Alkermes, Inc. ($408.15) |
| 2023 | $2,380 | 140 | ABBVIE INC. ($554.75) |
| 2022 | $3,483 | 175 | Alkermes, Inc. ($626.68) |
| 2021 | $4,121 | 214 | Teva Pharmaceuticals USA, Inc. ($660.38) |
All Payment Transactions
677 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: CNS | ||||||
| 12/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $28.29 | General |
| Category: Neuropsychiatry | ||||||
| 12/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $26.43 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $7.50 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $0.82 | General |
| Category: PSYCHIATRY | ||||||
| 11/08/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $24.01 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Central Nervous System | ||||||
| 11/06/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: Insomnia | ||||||
| 10/30/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $11.76 | General |
| Category: PSYCHIATRY | ||||||
| 10/17/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $30.58 | General |
| Category: Central Nervous System | ||||||
| 10/17/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: CNS | ||||||
| 10/16/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: CNS | ||||||
| 10/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $32.12 | General |
| Category: SCHIZOPHRENIA | ||||||
| 10/09/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: PSYCHIATRY | ||||||
| 10/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: CNS | ||||||
| 10/03/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $13.19 | General |
| Category: PSYCHIATRY | ||||||
| 10/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $3.61 | General |
| Category: CNS | ||||||
| 10/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $10.19 | General |
| Category: Neuropsychiatry | ||||||
| 10/02/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $3.57 | General |
| Category: Neuropsychiatry | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 287 | 1,186 | $172,110 | $58,595 |
| 2022 | 6 | 299 | 1,285 | $169,460 | $68,135 |
| 2021 | 6 | 236 | 976 | $129,051 | $54,092 |
| 2020 | 7 | 297 | 775 | $113,202 | $34,647 |
Total Patients
1,119
Total Services
4,222
Medicare Billing
$215,470
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 103 | 470 | $70,600 | $35,461 | 50.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 101 | 437 | $85,080 | $18,106 | 21.3% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 31 | 41 | $9,100 | $2,106 | 23.1% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2023 | 36 | 222 | $3,330 | $2,040 | 61.3% |
| 90838 | Psychotherapy with evaluation and management visit, 1 hour | Office | 2023 | 16 | 16 | $4,000 | $882.53 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 519 | $77,850 | $39,886 | 51.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 93 | 464 | $70,900 | $20,031 | 28.3% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 48 | 68 | $8,975 | $3,641 | 40.6% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2022 | 29 | 199 | $2,985 | $1,897 | 63.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,750 | $1,409 | 29.7% |
| 90838 | Psychotherapy with evaluation and management visit, 1 hour | Office | 2022 | 16 | 16 | $4,000 | $1,272 | 31.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 77 | 431 | $69,141 | $31,575 | 45.7% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 72 | 347 | $40,050 | $14,909 | 37.2% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 42 | 86 | $10,616 | $4,666 | 44.0% |
| 90838 | Psychotherapy with evaluation and management visit, 60 minutes | Office | 2021 | 13 | 19 | $4,750 | $1,210 | 25.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $3,295 | $1,025 | 31.1% |
| 90785 | Interactive complexity | Office | 2021 | 19 | 80 | $1,200 | $707.42 | 59.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 78 | 277 | $53,536 | $15,299 | 28.6% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 75 | 306 | $33,330 | $12,821 | 38.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 20 | 20 | $5,315 | $1,620 | 30.5% |
| 90838 | Psychotherapy, 60 minutes | Office | 2020 | 19 | 21 | $5,050 | $1,480 | 29.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 40 | 54 | $6,610 | $1,452 | 22.0% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 16 | 24 | $4,125 | $1,271 | 30.8% |
| 90785 | Interactive complexity | Office | 2020 | 49 | 73 | $5,235 | $705.63 | 13.5% |
About Lin Cai
Lin Cai is a Family healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2015. The National Provider Identifier (NPI) number assigned to this provider is 1578932521.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Lin Cai has received a total of $12,801 in payments from pharmaceutical and medical device companies, with $2,817 received in 2024. These payments were reported across 677 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($12,706).
As a Medicare-enrolled provider, Cai has provided services to 1,119 Medicare beneficiaries, totaling 4,222 services with total Medicare billing of $215,470. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Other Specialties Psychiatric/Mental Health
- Location Austin, TX
- Active Since 09/21/2015
- Last Updated 03/17/2018
- Taxonomy Code 363LF0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578932521
Products in Payments
- VRAYLAR (Drug) $1,564
- REXULTI (Drug) $1,556
- ARISTADA (Drug) $1,454
- CAPLYTA (Drug) $883.78
- AUSTEDO (Drug) $738.10
- INGREZZA (Drug) $697.22
- LATUDA (Drug) $679.61
- SPRAVATO (Drug) $560.93
- INVEGA SUSTENNA (Drug) $451.94
- Auvelity (Drug) $446.58
- TRINTELLIX (Drug) $425.14
- LYBALVI (Drug) $382.17
- ABILIFY MAINTENA (Drug) $370.65
- Dayvigo (Drug) $280.97
- HETLIOZ (Drug) $272.57
- AZSTARYS (Drug) $272.22
- Dyanavel XR (Drug) $184.67
- Austedo XR (Drug) $180.19
- Azstarys (Drug) $157.75
- ABILIFY MYCITE (Drug) $144.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Austin
Monique Mulvany, N.p, N.P
Family — Payments: $68,796
Family $68,796
Mrs. Chelsea Crilly, Fnp-C, FNP-C
Family — Payments: $29,209
Family $29,209
Selina Gawriluk, Fnp-C, FNP-C
Family — Payments: $16,908
Family $16,908
Michelle Escue, F.n.p, F.N.P
Family — Payments: $16,509
Family $16,509
Kaycee Frederick, Np, NP
Family — Payments: $14,585
Family $14,585
Megan Passe, Np-C, NP-C
Family — Payments: $14,260
Family $14,260